GNTA - Genenta to Participate at Upcoming Investor Conferences

MILAN, Italy and NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced today that management will be participating in the following upcoming investor conferences:

34th Annual ROTH Conference , Dana Point, California, U.S.

Maxim Group LLC 2022 Virtual Growth Conference

HC Wainwright Gene Therapy and Gene Editing Conference , virtual

8th Annual LSX World Congress , London, UK and virtual

Further information on these events may be found on the "News & Events" section of Genenta's Investor website at https://ir.genenta.com/news-events/events .

About Genenta Science

Genenta (www.genenta.com) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon™, which is under investigation in a phase 1/2 clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which should induces a durable immune response not restricted to pre-selected tumor antigens nor type and aimed at reaching solid tumors, avoid systemic toxicity, some of the main unresolved challenges in immuno-oncology.